Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Operating Cash Flow

Cash generated by the company's core business operations during the period.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow growth accelerates

Q1 FY2026 operating cash flow of $38.03M (cash outflow) rose 5.9% year over year, ahead of the -21.1% change in trailing-twelve-month operating cash flow. Sequentially, it rose 26.2% from the prior quarter. Over 3 fiscal years it compounded at +4.0% a year.

Context

  • Operating cash flow amounted to 9984.2% of revenue in FY2025, down 87220.3 pp from a year earlier.
  • Operating cash flow grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +5.9% holds above the trailing-twelve-month pace of -21.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$38.03M+26.2% QoQ
Last fiscal yearDec 2025
-$129.79M-33.2% YoY
LTMMar 2026
-$131.93M-21.1% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.9%——
1 year-33.2%——
3-year CAGR+4.0%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(129.79M) USD
Year-over-year change
+33.2%

Operating Cash Flow vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -21.1% is the lowest of 7, against a peer median of +34.0%.
  • Operating cash flow amounts to 10148.1% of revenue for INBX, versus a peer median of 629.0%.
INBX Competitors
Operating Cash Flow for INBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$251.97M USD+40.4%+26.7%224975.9%
GENBGenerate Biomedicines, Inc.FY2025$200.62M USD+70.4%—629.0%
IMTXImmatics N.V.LTM Mar 2026€184.13M EUR+15.3%—493.7%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$131.93M USD-21.1%+4.0%10148.1%
ABSIAbsci CorporationLTM Mar 2026$97.39M USD+27.5%+4.5%5304.6%
JANXJanux Therapeutics, Inc.LTM Mar 2026$77.55M USD+68.6%+24.2%358.8%
TECXTectonic Therapeutic, Inc.LTM Mar 2026$65.41M USD+4.0%-14.8%—
Peer median (excluding INBX) —+34.0%+14.4%629.0%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(81.77M)(145.23M)(239.73M)1.69B(140.06M)
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
Deferred Income Tax(9K)0000
Stock-Based Compensation15.05M20.45M24.85M58.52M11.14M
Change in Working Capital(17.52M)3.16M15.35M52.05M(7.61M)
Accounts Receivables(167K)130K(521K)381K243K
Inventory(11.03M)0000
Accounts Payables(4.64M)(705K)2.11M17.9M(3.3M)
Other Working Capital(1.67M)3.74M13.76M33.77M(4.56M)
Other Non-Cash Items2.73M5.09M5.03M(1.99B)4.25M
Operating Cash Flow(80.32M)(115.3M)(193.31M)(194.41M)(129.79M)
Capital Expenditures(864K)(686K)(4.59M)(2.6M)(31K)
Acquisitions (Net)55K0003K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(809K)(686K)(4.59M)(2.6M)(28K)
Debt Repayment000099.84M
Common Stock Issued40.2M129.74M201.96M71.68M1.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities83.77M128.81M000
Financing Cash Flow83.77M258.55M201.96M71.68M101.45M
Effect of Forex Changes00000
Net Change in Cash2.64M142.56M4.06M(125.33M)(28.38M)
Free Cash Flow(81.19M)(115.99M)(197.9M)(197.01M)(129.83M)

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.